

Solomon L Woldu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8752150/publications.pdf>

Version: 2024-02-01

103
papers

1,304
citations

430874

18
h-index

434195

31
g-index

104
all docs

104
docs citations

104
times ranked

1958
citing authors

#	ARTICLE	IF	CITATIONS
1	Guideline of guidelines: non-muscle-invasive bladder cancer. <i>BJU International</i> , 2017, 119, 371-380.	2.5	195
2	Improved survival after cytoreductive nephrectomy for metastatic renal cell carcinoma in the contemporary immunotherapy era: An analysis of the National Cancer Database. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 604.e9-604.e17.	1.6	77
3	Androgen Receptor Variants Mediate DNA Repair after Prostate Cancer Irradiation. <i>Cancer Research</i> , 2017, 77, 4745-4754.	0.9	56
4	Impact of hospital case volume on testicular cancer outcomes and practice patterns. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 14.e7-14.e15.	1.6	55
5	Discordance between Ureteroscopic Biopsy and Final Pathology for Upper Tract Urothelial Carcinoma. <i>Journal of Urology</i> , 2018, 199, 1440-1445.	0.4	53
6	Serum MicroRNA-371a-3p Levels Predict Viable Germ Cell Tumor in Chemotherapy-naïve Patients Undergoing Retroperitoneal Lymph Node Dissection. <i>European Urology</i> , 2020, 77, 290-292.	1.9	48
7	Pathologic response and surgical outcomes in patients undergoing nephrectomy following receipt of immune checkpoint inhibitors for renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 924-931.	1.6	42
8	Neoadjuvant SABR for Renal Cell Carcinoma Inferior Vena Cava Tumor Thrombus—Safety Lead-in Results of a Phase 2 Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 1135-1142.	0.8	36
9	Degarelix versus luteinizing hormone-releasing hormone agonists for the treatment of prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 825-832.	1.8	34
10	The impact of squamous histology on survival in patients with muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 353.e17-353.e24.	1.6	32
11	Real-World Application of Pre-Orchiectomy miR-371a-3p Test in Testicular Germ Cell Tumor Management. <i>Journal of Urology</i> , 2021, 205, 137-144.	0.4	28
12	Validating the predictors of outcomes after radical cystectomy for bladder cancer. <i>Cancer</i> , 2019, 125, 223-231.	4.1	27
13	Serum Small RNA Sequencing and miR-375 Assay Do Not Identify the Presence of Pure Teratoma at Postchemotherapy Retroperitoneal Lymph Node Dissection. <i>European Urology Open Science</i> , 2021, 26, 83-87.	0.4	26
14	Optimal sampling scheme in men with abnormal multiparametric MRI undergoing MRI-TRUS fusion prostate biopsy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 57-62.	1.6	24
15	New insights into germ cell tumor genomics. <i>Andrology</i> , 2019, 7, 507-515.	3.5	23
16	Update on epidemiologic considerations and treatment trends in testicular cancer. <i>Current Opinion in Urology</i> , 2018, 28, 440-447.	1.8	22
17	Usage and survival implications of surgical staging of inguinal lymph nodes in intermediate- to high-risk, clinical localized penile cancer: A propensity-score matched analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 159.e7-159.e17.	1.6	21
18	Preoperative predictive model and nomogram for disease recurrence following radical nephroureterectomy for high grade upper tract urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 758-764.	1.6	21

#	ARTICLE	IF	CITATIONS
19	Tissue-based biomarkers in prostate cancer. Expert Review of Precision Medicine and Drug Development, 2017, 2, 249-260.	0.7	20
20	What is the role of nephrectomy following complete response to checkpoint inhibitors?. Urology Case Reports, 2018, 18, 60-63.	0.3	20
21	Testicular germ cell tumor genomics. Current Opinion in Urology, 2017, 27, 41-47.	1.8	18
22	Therapeutic strategies for upper tract urothelial carcinoma. Expert Review of Anticancer Therapy, 2018, 18, 765-774.	2.4	18
23	Impact of Hospital Case Volume on Outcomes Following Radical Nephrectomy and Inferior Vena Cava Thrombectomy. European Urology Oncology, 2019, 2, 691-698.	5.4	18
24	Robotic Nephroureterectomy vs Laparoscopic Nephroureterectomy: Increased Utilization, Rates of Lymphadenectomy, Decreased Morbidity Robotically. Journal of Endourology, 2021, 35, 312-318.	2.1	18
25	Differences at Presentation and Treatment of Testicular Cancer in Hispanic Men: Institutional and National Hospital-based Analyses. Urology, 2018, 112, 103-111.	1.0	15
26	Preoperative predictors of nonorgan-confined disease in upper-tract urothelial carcinoma differ between China and the United States. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 88.e11-88.e18.	1.6	15
27	The Rho GTPase signalling pathway in urothelial carcinoma. Nature Reviews Urology, 2018, 15, 83-91.	3.8	15
28	Perioperative outcomes and cost of robotic vs open simple prostatectomy in the modern robotic era: results from the National Inpatient Sample. BJU International, 2021, 128, 168-177.	2.5	15
29	Incidence and Outcomes of Delayed Targeted Therapy After Cytoreductive Nephrectomy for Metastatic Renal-Cell Carcinoma: A Nationwide Cancer Registry Study. Clinical Genitourinary Cancer, 2018, 16, e1221-e1235.	1.9	14
30	Practice Patterns and Impact of Postchemotherapy Retroperitoneal Lymph Node Dissection on Testicular Cancer Outcomes. European Urology Oncology, 2018, 1, 242-251.	5.4	14
31	Site of extranodal metastasis impacts survival in patients with testicular germ cell tumors. Cancer, 2019, 125, 3947-3952.	4.1	14
32	Impact of circulating microRNA test (miRNA-371a-3p) on appropriateness of treatment and cost outcomes in patients with Stage I non-seminomatous germ cell tumours. BJU International, 2020, 128, 57-64.	2.5	14
33	Overcoming sociodemographic factors in the care of patients with testicular cancer at a safety net hospital. Cancer, 2020, 126, 4362-4370.	4.1	14
34	Modelling cost-effectiveness of a biomarker-based approach to neoadjuvant chemotherapy for muscle-invasive bladder cancer. BJU International, 2018, 122, 434-440.	2.5	13
35	Spotlight on atezolizumab and its potential in the treatment of advanced urothelial bladder cancer. OncoTargets and Therapy, 2017, Volume 10, 1487-1502.	2.0	12
36	Tackling non-muscle invasive bladder cancer in the clinic. Expert Review of Anticancer Therapy, 2017, 17, 467-480.	2.4	11

#	ARTICLE	IF	CITATIONS
37	Prospective evaluation of blue-light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer. <i>BJU International</i> , 2021, 127, 108-113.	2.5	11
38	Evaluation of the New American Urological Association Guidelines Risk Classification for Hematuria. <i>Journal of Urology</i> , 2021, 205, 1387-1393.	0.4	11
39	Intraoperative prophylactic intravesical chemotherapy to reduce bladder recurrence following radical nephroureterectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 737.e11-737.e16.	1.6	10
40	Metastasis-directed radiation therapy after radical cystectomy for bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 790.e1-790.e7.	1.6	10
41	The surgeon "scientist" a dying breed?. <i>Nature Reviews Urology</i> , 2016, 13, 698-699.	3.8	9
42	Metastatic Melanoma to the Bladder: Case Report and Review of the Literature. <i>Urology Case Reports</i> , 2017, 11, 33-36.	0.3	9
43	Prognostic significance of BAP1 expression in high-grade upper tract urothelial carcinoma: a multi-institutional study. <i>World Journal of Urology</i> , 2019, 37, 2419-2427.	2.2	9
44	Nationwide Patterns of Care for Stage II Nonseminomatous Germ Cell Tumor of the Testicle. <i>European Urology Oncology</i> , 2020, 3, 198-206.	5.4	9
45	Population-based analysis of cost and peri-operative outcomes between open and robotic primary retroperitoneal lymph node dissection for germ cell tumors. <i>World Journal of Urology</i> , 2021, 39, 1977-1984.	2.2	9
46	Improving diagnostic molecular tests to monitor urothelial carcinoma recurrence. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 1189-1199.	3.1	8
47	Does grossly complete transurethral resection improve response to neoadjuvant chemotherapy?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 736.e11-736.e18.	1.6	8
48	Stereotactic Body Radiation Therapy for Renal Cell Carcinoma with Inferior Vena Cava Thrombus "Initial Experience Report and Literature Review. <i>Kidney Cancer</i> , 2019, 3, 71-77.	0.4	7
49	Feasibility and Safety of Robotic Excision of Ipsilateral Retroperitoneal Recurrence After Nephrectomy for Renal Cell Carcinoma. <i>Urology</i> , 2020, 145, 159-165.	1.0	7
50	Demographic Factors Associated With Non-Guideline-Based Treatment of Kidney Cancer in the United States. <i>JAMA Network Open</i> , 2021, 4, e2112813.	5.9	7
51	PTRF independently predicts progression and survival in multiracial upper tract urothelial carcinoma following radical nephroureterectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 496-505.	1.6	6
52	Increased use of antihypertensive medications after partial nephrectomy vs. radical nephrectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 660.e17-660.e25.	1.6	5
53	Validation of Hyponatremia as a Prognostic Predictor in Multiregional Upper Tract Urothelial Carcinoma. <i>Journal of Clinical Medicine</i> , 2020, 9, 1218.	2.4	5
54	Phase II trial of stereotactic ablative radiation (SAbR) for oligometastatic kidney cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 311-311.	1.6	5

#	ARTICLE	IF	CITATIONS
55	Safety and feasibility of nephrectomy after receipt of immune checkpoint inhibitors for renal cell carcinoma.. Journal of Clinical Oncology, 2019, 37, 619-619.	1.6	5
56	Multi-institutional evaluation of the prognostic significance of EZH2 expression in high-grade upper tract urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 343.e1-343.e8.	1.6	4
57	Incidental Detection of Metastatic Penile Squamous-Cell Carcinoma With Anti-18F-Fluciclovine PET/CT in a Patient With Recurrent Prostate Cancer. Clinical Genitourinary Cancer, 2019, 17, e184-e186.	1.9	4
58	Enhanced Endoscopy with IMAGE1 S CHROMA Improves Detection of Nonmuscle Invasive Bladder Cancer During Transurethral Resection. Journal of Endourology, 2021, 35, 647-651.	2.1	4
59	Predictive capacity of miRNA-375 in identifying teratoma in post-chemotherapy retroperitoneal lymph node dissection (PC-RPLND).. Journal of Clinical Oncology, 2020, 38, 416-416.	1.6	4
60	Safety and Feasibility of Telehealth Only Preoperative Evaluation Before Minimally Invasive Robotic Urologic Surgery. Journal of Endourology, 2022, 36, 1070-1076.	2.1	4
61	The Significance of Preoperative Serum Sodium and Hemoglobin in Outcomes of Upper Tract Urothelial Carcinoma: Multi-Center Analysis Between China and the United States. Cancer Management and Research, 2020, Volume 12, 9825-9836.	1.9	3
62	Clinical utility of the AJCC 8th edition pT1 subclassification and impact on practice patterns in stage I seminoma. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 136.e19-136.e25.	1.6	3
63	PD-L1 expression and BCG response in nonmuscle invasive bladder cancer.. Journal of Clinical Oncology, 2022, 40, 545-545.	1.6	3
64	Predictive factors of diagnostic delay and effect on treatment patterns in testicular germ cell tumor patients. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 201.e1-201.e7.	1.6	3
65	Re: Sophia C. Kamran, Thomas Seisen, Sarah C. Markt, et al. Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer. Eur Urol 2018;73:262-270. European Urology, 2018, 73, e98-e99.	1.9	2
66	Stereotactic Ablative Radiotherapy (SAbR) in the Setting of Metastatic Nonseminomatous Germ Cell Tumor of Testis. Clinical Genitourinary Cancer, 2019, 17, e768-e771.	1.9	2
67	Interethnic differences in the impact of body mass index on upper tract urothelial carcinoma following radical nephroureterectomy. World Journal of Urology, 2021, 39, 491-500.	2.2	2
68	Survival by T Stage for Patients with Localized Bladder Cancer: Implications for Future Screening Trials. Bladder Cancer, 2021, 7, 23-31.	0.4	2
69	Simple Nephrectomy in a Tertiary Care Safety Net Hospital—Patient Characteristics, Causes, Cost, and Renal Function Implications. Urology, 2021, 149, 98-102.	1.0	2
70	Predictive model for systemic recurrence following cisplatin-based neoadjuvant chemotherapy and radical nephroureterectomy for high risk upper tract urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 788.e15-788.e21.	1.6	2
71	Re: ctDNA Guiding Adjuvant Immunotherapy in Urothelial Carcinoma. European Urology, 2021, 80, 517-518.	1.9	2
72	Validation of testicular germ cell tumor staging in nationwide cancer registries. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 838.e1-838.e6.	1.6	2

#	ARTICLE	IF	CITATIONS
73	Is Malignant Germ-Cell Tumor Associated With Cowden Syndrome?. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e429-e432.	1.9	1
74	Safety, Efficacy, and Impact on Quality of Life of Palliative Robotic Cystectomy for Advanced Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e129-e134.	1.9	1
75	Disparities in Pre-Orchiectomy Sperm Cryopreservation Among Testicular Cancer Patients at a Public Safety Net Hospital and a Private Tertiary Care Center. <i>Urology</i> , 2021, , .	1.0	1
76	Utilization and survival implications of a delayed approach to targeted therapy for metastatic renal cell carcinoma: A nationwide cancer registry study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 586-586.	1.6	1
77	The early impact of medicaid expansion on urologic malignancies in the United States. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 40, 103.e1-103.e1.	1.6	1
78	Performance characteristics of 18F-Fluciclovine positron emission tomography/computed tomography prior to retroperitoneal lymph node dissection.. <i>Journal of Clinical Oncology</i> , 2020, 38, 390-390.	1.6	1
79	Serum microRNA-371a-3p levels to predict viable germ cell tumor in chemotherapy-naïve patients undergoing retroperitoneal lymph node dissection.. <i>Journal of Clinical Oncology</i> , 2020, 38, 417-417.	1.6	1
80	Performance characteristics of 18F-fluciclovine positron emission tomography/computed tomography prior to retroperitoneal lymph node dissection. <i>Canadian Urological Association Journal</i> , 2021, 16, E167-E172.	0.6	1
81	Re: Efficacy of High-intensity Local Treatment for Metastatic Urothelial Carcinoma of the Bladder: A Propensity Scoreâ€“Weighted Analysis from the National Cancer Data Base. <i>European Urology</i> , 2016, 70, 893.	1.9	0
82	Single nucleotide polymorphisms of the vascular endothelial growth factor receptor â€“ a promising biomarker in metastatic renal cell carcinoma. <i>BJU International</i> , 2016, 118, 847-848.	2.5	0
83	Reply. <i>Urology</i> , 2018, 112, 111.	1.0	0
84	Reply by Authors. <i>Urology Practice</i> , 2018, 5, 131-131.	0.5	0
85	Prospective Monitoring and Adapting Strategies for Prevention of Infection Following Transrectal Prostate Procedures. <i>Urology Practice</i> , 2018, 5, 124-131.	0.5	0
86	Clinical outcomes of a cohort of patients with bulky, clinically node-positive bladder cancer undergoing radical cystectomy in the contemporary era. <i>Canadian Urological Association Journal</i> , 2020, 15, E286-E289.	0.6	0
87	Validation of testicular germ cell tumor (GCT) staging in nationwide cancer registries.. <i>Journal of Clinical Oncology</i> , 2021, 39, 383-383.	1.6	0
88	Sarcopenia prior to and following chemotherapy to predict morbidity in patients undergoing post-chemotherapy retroperitoneal lymphadenectomy (PC-RPLND).. <i>Journal of Clinical Oncology</i> , 2021, 39, 381-381.	1.6	0
89	Reply to So, now what?: Reflections on socioeconomic factors, testicular cancer, and health care accessibility. <i>Cancer</i> , 2021, 127, 1347-1348.	4.1	0
90	Encouraging Outcomes Allow Patient-Guided Treatment Strategies for Stage I Pure Testicular Teratoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 3465-3467.	1.5	0

#	ARTICLE	IF	CITATIONS
91	Editorial Comment. Journal of Urology, 2021, 205, 1620-1620.	0.4	0
92	Prognostic value of PD-1 and PD-L1 expression in patients with high-grade urothelial carcinoma of the upper urinary tract.. Journal of Clinical Oncology, 2017, 35, 358-358.	1.6	0
93	Editorial Comment. Journal of Urology, 2019, 201, 901-901.	0.4	0
94	Pathologic response and surgical outcomes in patients undergoing nephrectomy after receipt of immune checkpoint inhibitors for renal cell carcinoma.. Journal of Clinical Oncology, 2019, 37, e16102-e16102.	1.6	0
95	Overcoming sociodemographic factors in the care of testicular cancer patients at a safety net hospital.. Journal of Clinical Oncology, 2020, 38, 398-398.	1.6	0
96	Effect of increasing Medicaid coverage in Medicaid expansion states on stage at presentation for urologic malignancies.. Journal of Clinical Oncology, 2020, 38, 400-400.	1.6	0
97	Evaluation of a risk-adapted strategy in the primary surgical management of clinical stage IIA testicular cancer.. Journal of Clinical Oncology, 2022, 40, 414-414.	1.6	0
98	Molecular analysis of primary testicular germ cell tumor and matched metastatic teratomas.. Journal of Clinical Oncology, 2022, 40, 425-425.	1.6	0
99	Dose-Intensified Stereotactic Ablative Radiation for Localized Prostate Cancer. Frontiers in Oncology, 2022, 12, 779182.	2.8	0
100	Evaluating the discriminatory capacity of miR-371A-3P in the context of pure seminomatous testicular cancer metastases.. Journal of Clinical Oncology, 2022, 40, 424-424.	1.6	0
101	Actionable genomic landscapes from a real-world cohort of localized urothelial carcinoma patients.. Journal of Clinical Oncology, 2022, 40, 525-525.	1.6	0
102	Role of preoperative albumin in predicting risk of postoperative complications in patients undergoing post-chemotherapy retroperitoneal lymph node dissection (PC-RPLND).. Journal of Clinical Oncology, 2022, 40, 416-416.	1.6	0
103	Outcomes of Patients with Bacillus Calmette-GuÃ©rin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer as Defined by the U.S. Food and Drug Administration. Bladder Cancer, 2022, , 1-12.	0.4	0